Cytomos secures £1.6m in additional seed funding from Archangels
Archangels led the financing round to support the development of the company cell analysis platform.
Share allotment filed at Companies House
Edinburgh-based life science business that has created a proprietary cell analysis platform called Cytomos Dielectric Spectroscopy.
Cytomos has secured £1.6m in additional seed funding to progress the development and qualification of its novel cell analysis platform, Cytomos Dielectric Spectroscopy. The financing round was led by existing backer Archangels, with participation from Scottish Enterprise and Old College Capital.
The capital will be used to grow the team, deliver the next generation sensor and analytics for real-time cell monitoring, and expand customer engagement. This funding follows a productive period for the company involving prototype field testing and the securing of a key US patent for its technology.
The firm aims to address unmet needs in the biopharma sector by providing a portable, low-cost, and scalable alternative to traditional cell analysis methods, helping to streamline drug development, vaccine production, and cell and gene therapy manufacture.
From the founder
"On behalf of our Board and employees I would like to thank our investors for their continued support of Cytomos. We now have the growth capital required to advance the development of our novel process analytical technology platform to the next phase of prototype evaluation with our strategic partners. This is an important milestone in the journey to deliver our mission to enable the development and manufacture of life saving biologic therapies"
Alan Raymond
Executive Chairman at Cytomos
Investor perspective
"The demand for single-cell and label-free analysis tools is soaring and the CDS platform developed by Cytomos is uniquely placed to provide a low cost, real-time format that is highly scalable. and easy to operate with a small footprint. We are excited by its potential to be truly disruptive and look forward to supporting the team as the businesses further develops its commercial viability."
Sarah Hardy
Head of New Investments and Director, Archangels
Use of funds
- 01Grow the team
- 02Continue product development
